{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000055","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.573394+00:00","generated_at":"2026-06-20T14:36:07.231646+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexaria CEO letter details FDA pre-IND success, new Japan client, no 2022 equity raise","bullets":["FDA pre-IND meeting cleared path toward formal IND filing for DehydraTECH-CBD hypertension program; Phase 1(b) study expected in 2023.","Signed first Asian client Premier Wellness Science with minimum quarterly payments totaling $4.53M over five years.","Did not raise equity in 2022; management preserved capital; can survive most of 2023 without additional funding.","Human nicotine study dosing began in December; results expected early 2023.","Animal seizure study showed DehydraTECH-CBD competitive with Epidiolex; new R&D into dementia and diabetes underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000055","json":"https://secwatch.observer/filing/0001640334-23-000055.json","markdown":"https://secwatch.observer/filing/0001640334-23-000055.md","text":"https://secwatch.observer/filing/0001640334-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000055/0001640334-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000055/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:36:07.231646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}